Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention
2024-514868-11-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aortic stenosis (AS), heart failure (HF) and chronic kidney disease (CKD) comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Primary composite myocardial and renal performance endpoint at 12 months. Planned start Jul 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
aortic stenosis (AS)heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-514868-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514868-11-00.